top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Recent Biotech Funding Activity - March 18th

Check out the following recent activity in the biopharma funding space. This mix of private investments and public grants fuels important research and development across the industry. Take a closer look at some of the notable updates for this week:

– Private Funding Rounds –

Siolta Therapeutics

🏦 Raised $12M in Series C financing for clinical development co-led by SymBiosis and Khosla Ventures to advance the development of STMC-103H for atopic disorders. 


🏦 Closed €128M Series B2 funding round co-led by EQT Life Sciences and Nextech Invest to progress the development of their ADC drug pipelines.

Asgard Therapeutics

🏦 Secured $32M Series A financing from J&J, Novo, and Boehringer to advance its lead program candidate, AT-108.

Relation Therapeutics

🏦 Raised $35M in seed funding led by DCVC & NVentures totaling $60M to advance its therapeutic pipeline for Osteoporosis. 

Alithea Genomics 

🏦 Raised $3.2M from seed financing extension led by Novalis Biotech to further commercialize its unique RNA seq. products and advance new technology developments. 

Mission Therapeutics 

🏦 Raised £25.2M led by several investors to progress clinical candidates (MTX325 and MTX652) in the area of mitophagy.

– Grants –

Gilgamesh Pharmaceuticals

🏦 Awarded $14M NIDA grant to advance GM-3009 treating opioid use disorder.


🏦 Awarded €1.5M grant from the Walloon Government for the EXOFASTTRACK project dedicated to the development of multiple therapeutic exosomes.


🏦 Received €1M Non-dilutive Innovation Grant from Bpifrance to support the development of CER-001 treating severe indications in ophthalmology. 

Theromics Inc. 

🏦 Granted $1M STTRE Ph2 grant from the National Science Foundation for the innovative ablation therapy technology (HeatSYNC™).

– Equity Financing –


🏦 Oversubscribed private placement of $150M led by Deep Track Capital.

Regulus Therapeutics 

🏦 Secured $100M private placement.

Lexeo Therapeutics 

🏦 Closed oversubscribed $95M equity financing.

Unicycive Therapeutics

🏦 $50M private placement led by Octagon Capital & Great Point Partners. 

Eupraxia Pharmaceuticals 

🏦 Closed overnight marketed offering C$33.9M.

Sellas Life Sciences 

🏦 $20M registered direct offering and concurrent private placement.


🏦 Completed upsized $12M equity placing.

Cognition Therapeutics 

🏦 Closed $11.5M public offering.

Delcath Systems 

🏦 $7M private placement.

ASLAN Pharmaceuticals 

🏦 Entered into a $5M registered direct offering.

Scorpius Holdings 

🏦 Closed $1.5M public offering.


🏦 Closed $223.8K private placement offering.


Interested in these updates? Get the full update each week → 

Article History:

RF, DV (03/18/24)


bottom of page